echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Deyi Sunshine Biotechnology initiates the first human clinical trial of a new interferon lambda chimera in the United States

    Deyi Sunshine Biotechnology initiates the first human clinical trial of a new interferon lambda chimera in the United States

    • Last Update: 2021-06-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Prosit Sole Biotechnology (Prosit Sole Biotechnology) announced the launch of the first human ("FIH") phase I clinical trial of PSP001 (pegylated human interferon λ1 and λ3 chimeric protein) in the United States
    .
    PSP001 is a new, long-acting and highly effective interferon lambda chimera injection.


    It is the first interferon lambda drug to enter the clinical stage in China


    Type III interferons (IFN's), also known as λ interferons (IFNλ's), are new members of the interferon family discovered in recent years
    .
    Its receptor IFNλR1 is mainly distributed on the surface of epithelial mucosal cells, such as the mucosal surface of the respiratory tract, gastrointestinal tract and liver


    .


    "Chronic norovirus enteritis in immunocompromised people is an urgent medical need to be solved
    .
    " Dr.


    Hongyu Liu, CEO of Deyi Sunshine Biotechnology, said: "There is currently no approved treatment for this type of treatment in special populations.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.